[俄罗斯联邦和白俄罗斯共和国按照ALL-BFM-90m方案治疗儿童急性淋巴细胞白血病]

[Treatment of acute lymphoblastic leukemia in children according to the ALL-BFM-90m protocol in the Russian Federation and the Republic of Belarus].

作者信息

Miakova N V, Aleĭnikova O V, Hartmann R, Rudneva A E, Trubina N M, Fechina L G, Timakov A M, Shamardina A V, Lebedev V V, Varfolomeeva S Iu, Dudkin S D, Dyshlevaia Z M, Timofeeva V N, Rumiantsev A G, Henze H, Karachunskiĭ A I

机构信息

Research Institute of Pediatric Hematology and Oncology, Ministry of Health of the RF, Russian Children's Clinical Hospital, Moscow.

出版信息

Vopr Onkol. 2002;48(3):347-51.

PMID:12455360

Abstract

Prognosis for children treated according to the BFM-90m protocol (Berlin-Frankfurt-Munster Group) for acute lymphoblastic leukemia (ALL) improved significantly as compared with previous modalities. Methotrexate was used in the dose of 1,000 mg/m2, 36 h. The paper presents the 10-year results for this modification. Patients aged 0-15 years were treated at hematological hospitals of Moscow, other Russian towns and in Minsk, Belarus, (July 5, 1990-November 11, 2000). BFM-90m treatment was given to 682 children out of 1,326 with primary diagnosis of ALL; a comparative trial of the MB-91 protocol hed been carried out at the same clinics since 1991. During 10 years, recurrence-free survival was 72% while overall survival--77%. Toxicity of side-effects was tolerable. The BFM-90m treatment showed significantly better results in both countries.

摘要

与之前的治疗方式相比，按照BFM - 90m方案（柏林-法兰克福-明斯特组）治疗的急性淋巴细胞白血病（ALL）患儿的预后有显著改善。甲氨蝶呤的使用剂量为1000 mg/m²，用药时间为36小时。本文介绍了这一改良方案的10年结果。年龄在0至15岁的患者在莫斯科、俄罗斯其他城镇以及白俄罗斯明斯克的血液病医院接受治疗（1990年7月5日至2000年11月11日）。1326例初诊为ALL的患儿中，682例接受了BFM - 90m治疗；自1991年起，同一诊所对MB - 91方案进行了对比试验。10年间，无复发生存率为72%，总生存率为77%。副作用的毒性是可耐受的。在这两个国家，BFM - 90m治疗均显示出明显更好的效果。